



# **Cohere Medicare Advantage Policy – Cardiac Contractility Modulation (CCM)**

*Clinical Guidelines for Medical Necessity Review*

**Version:** 1  
**Effective Date:** October 24, 2024

# Important Notices

## Notices & Disclaimers:

**GUIDELINES ARE SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION-MAKING OF END USERS.**

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine the medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third-party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision-making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice. This policy may be superseded by existing and applicable Centers for Medicare & Medicaid Services (CMS) statutes.

© 2024 Cohere Health, Inc. All Rights Reserved.

## Other Notices:

HCPCS® and CPT® copyright 2024 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

## Guideline Information:

**Specialty Area:** Cardiovascular Disease

**Guideline Name:** Cohere Medicare Advantage Policy - Cardiac Contractility Modulation (CCM)

**Date of last literature review:** 10/22/2024

**Document last updated:** 10/23/2024

**Type:** ☒ Adult (18+ yo) | ☒ Pediatric (0-17 yo)

## **Table of Contents**

<b>Important Notices</b>	<b>2</b>
<b>Medical Necessity Criteria</b>	<b>4</b>
<b>Service: Cardiac Contractility Modulation (CCM)</b>	<b>4</b>
Benefit Category	4
Not Applicable	4
Related CMS Documents	4
Recommended Clinical Approach	4
Evaluation of Clinical Harms and Benefits	4
Medical Necessity Criteria	6
Indications	6
Non-Indications	6
Level of Care Criteria	6
Procedure Codes (CPT/HCPCS)	6
<b>Medical Evidence</b>	<b>8</b>
<b>Clinical Guideline Revision History/Information</b>	<b>12</b>

# Medical Necessity Criteria

## ***Service: Cardiac Contractility Modulation (CCM)***

### **Benefit Category**

Not Applicable

### **Related CMS Documents**

Please refer to [CMS Medicare Coverage Database](#) for the most current applicable CMS National Coverage.

- There are no NCDs and/or LCDs for cardiac contractility modulation (CCM)

### **Recommended Clinical Approach**

**This service is clinically unproven and not medically necessary.** Cardiac contractility modulation (CCM) is a device-based therapy proposed for heart failure (HF) patients with decreased left ventricular ejection fraction (LVEF) who are not candidates for other treatments such as cardiac resynchronization therapy.<sup>1</sup> Electrical impulses delivered to the heart muscle are purported to assist the heart in pumping blood more effectively and potentially reduce symptoms such as breathlessness, fatigue, and lower extremity edema.<sup>2-5</sup>

### **Evaluation of Clinical Harms and Benefits**

Cohere Health uses the criteria below to ensure consistency in reviewing the conditions to be met for coverage of cardiac contractility modulation (CCM). This process helps prevent incorrect denials and inappropriate approvals of medically necessary services. Specifically, limiting incorrect approvals reduces the risks associated with unnecessary procedures, such as complications from surgery, infections, and prolonged recovery times.

The potential clinical harms of using these criteria may include:

- Meta-analysis of randomized controlled trials (RCTs) of all-cause mortality outcomes of usage of cardiac contractility monitoring (CCM)

in patients with dilated cardiomyopathy and ineligible for cardiac resynchronization therapy (CRT) revealed no significant reduction in all-cause mortality compared to standard therapy.<sup>2</sup>

- CCM has not shown any impact on hospitalization or death in patients with cardiomyopathy in randomized controlled trials (RCTs).<sup>6-9</sup>
- Hospitalizations have occurred more frequently for patients with CCM than those with cardiac resynchronization therapy and defibrillator (CRT-D).<sup>10</sup>
- Increased healthcare costs and complications from the inappropriate use of emergency services and additional treatments.

The clinical benefits of using these criteria include:

- A retrospective study comparing patients with cardiac contractility modulation (CCM) versus those with cardiac resynchronization therapy with defibrillator (CRT-D) showed that intrinsic QRS width was stable with CCM.<sup>10</sup>
- A study comparing the Optimizer Smart and the Optimizer Smart Mini CCM devices concluded that in both randomized and nonrandomized clinical trials, New York Heart Association (NYHA) Class II-III patients with left ventricular ejection fraction (LVEF) between 25% and 45% most often benefited from CCM therapy.<sup>5</sup>
- Four randomized controlled trials (RCTs) have shown benefits in exercise capacity and quality of life (QOL) with CCM therapy.<sup>6-9</sup>
- A 2-year multi-site evaluation of CCM in patients with heart failure concluded that CCM provides a safe and effective long-term symptomatic and functional improvement in heart failure independent of baseline LVEF and was associated with a safety profile similar to published device trials.<sup>11</sup>
- Enhanced overall patient satisfaction and healthcare experience.

This policy includes provisions for expedited reviews and flexibility in urgent cases to mitigate risks of delayed access. Evidence-based criteria are employed to prevent inappropriate denials and ensure that patients receive medically necessary care. The criteria aim to balance the need for effective treatment with the minimization of potential harms, providing numerous clinical benefits in helping avoid unnecessary complications from inappropriate care.

In addition, using these criteria will likely decrease inappropriate denials by creating a consistent set of review criteria, thereby supporting optimal patient outcomes and efficient healthcare utilization.

### **Medical Necessity Criteria**

#### **Indications**

- **Cardiac contractility monitoring (CCM)** is considered appropriate if **ANY** of the following is **TRUE**:
- ◆ This procedure is clinically unproven and not medically necessary. There is inconclusive evidence of its effectiveness.

#### **Non-Indications**

- **Cardiac contractility monitoring (CCM)** is not considered appropriate if **ANY** of the following is **TRUE**:
- ◆ This is not applicable, as there are no indications.

### **Level of Care Criteria**

None

### **Procedure Codes (CPT/HCPCS)**

<b>CPT/HCPCS Code</b>	<b>Code Description</b>
0408T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrodes
0409T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only
0410T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic

	parameters; atrial electrode only
0411T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only
0412T	Removal of permanent cardiac contractility modulation system; pulse generator only
0413T	Removal of permanent cardiac contractility modulation system; transvenous electrode (atrial or ventricular
0414T	Removal and replacement of permanent cardiac contractility modulation system pulse generator only
0415T	Repositioning of previously implanted cardiac contractility modulation transvenous electrode, (atrial or ventricular lead)
0416T	Relocation of skin pocket for implanted cardiac contractility modulation pulse generator
0417T	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system
0418T	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable cardiac contractility modulation system

**Disclaimer:** G, S, I, and N Codes are non-covered per CMS guidelines due to their experimental or investigational nature.

## Medical Evidence

Nadeem and colleagues (2020) conducted a systematic review and updated meta-analysis of randomized controlled trials regarding all-cause mortality outcomes of usage of cardiac contractility monitoring (CCM) in patients with dilated cardiomyopathy who were ineligible for cardiac resynchronization therapy (CRT). Patients in this group had dilated cardiomyopathy and were divided into a CCM group and a standard therapy group and were followed for 12 weeks or longer. In their analysis of 930 patients, the CCM therapy group showed no significant reduction in all-cause mortality compared to the standard therapy group. The researchers concluded that there was a need for a large, randomized, controlled trial to determine CCM efficacy.<sup>2</sup>

Pipilas et al. (2023) published a systematic literature review regarding the current and future directions of CCM for heart failure. At the time of their review, only two devices, the Optimizer Smart and the Optimizer Smart Mini had received FDA approval. Their review concluded that in both randomized and nonrandomized clinical trials, New York Heart Association (NYHA) Class II-III patients with left ventricular ejection fraction between 25% and 45% most often benefited from CCM therapy. They stated that a positive effect exists with CCM; however, verification and further study in prospective, randomized controlled trials is necessary.<sup>5</sup>

In a 2016 systematic review, Abi-Samra and Gutterman discussed the clinical results of the current literature at that time. FDA-approved pharmacological and device-based treatments for heart failure with reduced ejection fraction (HFrEF) were stated to be limited, and CCM could fill the gap in current treatment for selected patients. Regarding long-term outcomes, the writers discuss retrospective trial outcomes and acknowledge that at that time, there had been no prospective CCM trials with mortality as a primary outcome. The need for such a prospective randomized trial is emphasized. Special applications and evaluations in CCM use include expansion of duration of daily CCM stimulus, use in cardiac resynchronization therapy (CRT) failures, heart failure with preserved ejection fraction, and atrial fibrillation.<sup>4</sup>

According to the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure, four randomized controlled trials (RCTs) have shown benefits in



exercise capacity and quality of life (QOL); however, as of yet, no benefits in reducing death or hospitalizations have been shown.<sup>12</sup>

# References

1. U.S. Food and Drug Administration (FDA). Summary of safety and effectiveness data (SSED). Optimizer Smart system. Published March 21, 2019. <https://www.fda.gov>.
2. Nadeem M, Tariq EF, Aslam HM, Illahi Y, Shah R. All-cause mortality outcomes of usage of cardiac contractility modulation in patients with dilated cardiomyopathy ineligible for cardiac re-synchronization therapy: an updated meta-analysis of randomized controlled trials. *Cureus*. 2020;12(9):e10627. Published 2020 Sep 24. doi: 10.7759/cureus.10627. PMID: 33123440.
3. Borggreffe M, Mann D. Cardiac contractility modulation in 2018. *Circulation*. 2018;138:2738–2740. doi: 10.1161/circulationaha.118.036460. PMID: 30565990.
4. Abi-Samra F, Gutterman D. Cardiac contractility modulation: a novel approach for the treatment of heart failure. *Heart Fail Rev*. 2016;21(6):645–660. doi: 10.1007/s10741-016-9571-6. PMID: 27394714.
5. Pipilas DC, Hanley A, Singh JP, Mela T. Cardiac Contractility modulation for heart failure: current and future directions. *J Soc Cardiovasc Angiogr Interv*. 2023;2(6Part B):101176. Published 2023 Dec 4. doi: 10.1016/j.jscai.2023.101176. PMID: 39131075.
6. Neelagaru SB, Sanchez JE, Lau SK, et al. Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. *Heart Rhythm*. 2006;3(10):1140–1147. doi: 10.1016/j.hrthm.2006.06.031. PMID: 17018340.
7. Borggreffe MM, Lawo T, Butter C, et al. Randomized, double-blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. *Eur Heart J*. 2008;29(8):1019–1028. doi: 10.1093/eurheartj/ehn020. PMID: 18270213.
8. Kadish A, Nademanee K, Volosin K, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure [published correction appears in *Am Heart J*. 2011 Jun;161(6):1220]. *Am Heart J*. 2011;161(2):329–337.e3372. doi: 10.1016/j.ahj.2010.10.025. PMID: 21315216.
9. Abraham WT, Kuck KH, Goldsmith RL, et al. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation [published correction appears in *JACC Heart Fail*. 2023 Jan;11(1):132. doi:

- 10.1016/j.jchf.2022.11.003]. *JACC Heart Fail.* 2018;6(10):874–883. doi: 10.1016/j.jchf.2018.04.010. PMID: 29754812.
10. Yucel G, Gaasch L, Kodeih A, et al. Device-therapy in chronic heart failure: Cardiac contractility modulation versus cardiac resynchronization therapy. *ESC Heart Fail.* Published online September 29, 2024. doi: 10.1002/ehf2.15067. PMID: 39344273.
11. Müller D, Remppis A, Schauerte P, et al. Clinical effects of long-term cardiac contractility modulation (CCM) in subjects with heart failure caused by left ventricular systolic dysfunction. *Clin Res Cardiol.* 2017;106(11):893–904. doi: 10.1007/s00392-017-1135-9. PMID: 28685207.
12. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2022;79(17):1757–1780. doi: 10.1016/j.jacc.2021.12.011. PMID: 35379504.

# Clinical Guideline Revision History/Information

Original Date: October 24, 2024		
Review History		